Equity Profile

ARWR

Arrowhead Pharmaceuticals, Inc.

Health CareBiotechnology$12.1B

Aug6Thu

Pre-Earnings Brief

UpcomingQ3-2026After Close5:00 PM EDT

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines that treat serious diseases by targeting the underlying causes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

$-1.49

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$64M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines that treat serious diseases by targeting the underlying causes. With a market cap of $12 billion, its innovations in RNA-targeted therapies are significant in the health care sector, particularly as the demand for advanced treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q2-2026, Arrowhead reported an EPS of $-0.93, which was better than the expected $-1.18, resulting in a positive surprise. However, revenue figures were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Focus on advancing pipeline products.
Commitment to managing costs effectively.
Plans to enhance partnerships and collaborations.

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Arrowhead's upcoming earnings, expecting a loss but looking for improvements in revenue and cost management. The consensus EPS estimate reflects ongoing challenges in the biotech sector.

Bull Case

If Arrowhead can exceed revenue expectations and show progress in its drug pipeline, it could signal strong future growth potential, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides weak guidance, it could raise concerns about its financial health and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$-1.49

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

Revenue

$64M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Arrowhead's revenue meet or exceed the consensus estimate of $64M?

Revenue performance is critical to assess the company's market demand and overall financial health, especially given the previous quarter's lack of revenue disclosure.

What updates will management provide regarding the progress of its drug pipeline?

Investors will be keen to hear about advancements in key products, as this will influence future growth prospects and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Arrowhead's revenue potential due to recent advancements in its pipeline that have not been fully factored in.

Supporting Evidence

The company has a history of surprising on the upside, as seen in Q2-2025.

Options pricing suggests a significant move, indicating that traders expect more volatility than the consensus reflects.

Recent positive developments in the biotech sector may not be fully accounted for in current estimates.

Key Risk

If revenue comes in above $64M, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Arrowhead's ability to generate revenue and advance its drug development against the backdrop of ongoing challenges in the biotech industry.

Bull Confirmed If

Revenue exceeding $64M and positive updates on pipeline progress would confirm the bull case.

Bear Confirmed If

Revenue falling significantly below $64M or negative commentary on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations and raises guidance, history suggests a potential average one-day move of +2.86%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement as investors digest the information.

Miss

Should Arrowhead miss on both EPS and revenue, history suggests a potential average one-day move of -0.17%, indicating a negative market reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new partnerships.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for Arrowhead's products.
4Any commentary on regulatory progress or challenges.
5Future guidance on revenue expectations for the next quarter.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing medicines that treat serious diseases by targeting the underlying causes....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

$-1.49

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$64M

Wall Street expectations, options signals, track record, and call prep available with Pro.

ARWR Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

+322.88%

Avg Stock Reaction

+0.59%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing pipeline products.
Commitment to managing costs effectively.
Plans to enhance partnerships and collaborations.

Expectations

Wall Street Expectations

Bull Case

If Arrowhead can exceed revenue expectations and show progress in its drug pipeline, it could signal strong future growth potential, leading to a positive market reaction.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides weak guidance, it could raise concerns about its financial health and lead to a negative stock reaction.

Key Metrics to Watch

EPS

$-1.49

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses relative to its revenue.

Revenue

$64M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Arrowhead's revenue meet or exceed the consensus estimate of $64M?

Revenue performance is critical to assess the company's market demand and overall financial health, especially given the previous quarter's lack of revenue disclosure.

What updates will management provide regarding the progress of its drug pipeline?

Investors will be keen to hear about advancements in key products, as this will influence future growth prospects and investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Arrowhead's revenue potential due to recent advancements in its pipeline that have not been fully factored in.

Supporting Evidence

The company has a history of surprising on the upside, as seen in Q2-2025.

Options pricing suggests a significant move, indicating that traders expect more volatility than the consensus reflects.

Recent positive developments in the biotech sector may not be fully accounted for in current estimates.

Key Risk

If revenue comes in above $64M, it could challenge the current bearish sentiment and shift investor expectations.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing Arrowhead's ability to generate revenue and advance its drug development against the backdrop of ongoing challenges in the biotech industry.

Bull Confirmed If

Revenue exceeding $64M and positive updates on pipeline progress would confirm the bull case.

Bear Confirmed If

Revenue falling significantly below $64M or negative commentary on the drug pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±21.53%

Historical Avg

±3.5%

Pricing rich

The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±21.5% while ARWR has averaged ±3.5% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.7%

30d HV

50.9%

Calls (20K)P/C Ratio: 0.16Puts (5K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Arrowhead beats expectations and raises guidance, history suggests a potential average one-day move of +2.86%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations but management's commentary is cautious, the stock may experience muted movement as investors digest the information.

Miss

Should Arrowhead miss on both EPS and revenue, history suggests a potential average one-day move of -0.17%, indicating a negative market reaction.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the drug pipeline and any new partnerships.
2Details on cost management strategies and their impact on profitability.
3Insights into market demand for Arrowhead's products.
4Any commentary on regulatory progress or challenges.
5Future guidance on revenue expectations for the next quarter.